Louis G. Lange - May 1, 2025 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Role
Director
Signature
/s/ Louise Kooij by Power of Attorney from Louis G. Lange
Stock symbol
NAMS
Transactions as of
May 1, 2025
Transactions value $
$0
Form type
4
Date filed
5/2/2025, 04:55 PM
Previous filing
Apr 21, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
LANGE LOUIS G Director C/O NEWAMSTERDAM PHARMA COMPANY N.V., GOOIMEER 2-35, NAARDEN, NETHERLANDS /s/ Louise Kooij by Power of Attorney from Louis G. Lange 2025-05-02 0001238401

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NAMS Ordinary Shares Options Exercise $0 +69 +0.25% $0.00 28.1K May 1, 2025 See Footnote F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NAMS Restricted Stock Unit Options Exercise -69 -50.36% 68 May 1, 2025 Ordinary Shares 69 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares are held directly by LGLange III Trust DTD10 (the "Trust") for the benefit of the Reporting Person.
F2 Each RSU represents a contingent right to receive one ordinary share.
F3 3,102 RSUs vested upon grant, 69 RSUs vested on April 1, 2025 and 69 RSUs vested on May 1, 2025. The 68 remaining RSUs will vest on June 1, 2025, subject to the Reporting Person's continued service with the issuer as of each of the vesting date.
F4 The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date under the BCA (the "Closing Date"). The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date.